Management and outcomes of hypertrophic cardiomyopathy in young adults

Archive ouverte

Baron, Émilie | Karam, Nicole | Donal, Erwan | Puscas, Tania | Mirabel, Mariana | Bacher, Anne | Wahbi, Karim | Mazzella, Jean-Michael | Jeunemaitre, Xavier | Reant, Patricia | Hagège, Albert

Edité par CCSD ; Elsevier ; Société française de cardiologie [2008-....] -

International audience. Background - Management of young adults with hypertrophic cardiomyopathy (HCM) is challenging. Aims - To evaluate the profile of young adults (16-25 years) with HCM included in the French prospective HCM registry. Methods - Patients were compared according to occurrence of major adverse cardiac events (MACE), comprising sudden cardiac death (SCD) events (implantable cardioverter defibrillator [ICD] discharge, SCD, sustained ventricular tachycardia), atrial fibrillation/embolic stroke, heart failure hospitalisation and unexplained syncope, at a mean follow-up of 4.4±2.2 years. Results - At baseline, among 61 patients (20.5±3.0 years; 16 women, 26.2%), 13 (21.3%) had a prophylactic ICD, 24.6% a family history of SCD, 29.5% obstruction, 86.0% magnetic resonance imaging myocardial fibrosis, 11.8% abnormal exercise blood pressure and 52.8% a European Society of Cardiology (ESC) 5-year SCD score<4% (24.5%≥6%). At follow-up, 15 patients (24.6%; seven women; all with fibrosis) presented 17 MACE, comprising: SCD events (n=7, 41.2%; including three patients with an ICD, five with at least one SCD major classical risk factor and an ESC score≥5% and two with no risk factors and an ESC score<4%); atrial fibrillation/stroke (n=6, 35.3%); heart failure (n=1, 5.9%); syncope (n=3, 17.6%). An ICD was implanted in 11 patients (four for secondary prevention), but in only 61.5% of patients with a score≥6%. Only obstruction significantly increased MACE risk (odds ratio 3.96; P=0.035), with a non-significant trend towards a lower risk in men (OR 0.29; P=0.065). Conclusions - In young adults with HCM, MACE are common in the short term, especially in obstructive HCM and women, mostly arrhythmic in origin. Prophylactic ICD implantation is frequent and does not strictly follow the guidelines, while the use of European/USA guidelines is helpful but imperfect in identifying SCD risk.

Suggestions

Du même auteur

Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life estimation from the French REgister of hypertrophic cardioMYopathy (REMY)

Archive ouverte | Parodi, Alessandro | CCSD

International audience. Background: The efficacy of current pharmacological therapies in hypertrophic cardiomyopathy is limited. A cardiac myosin inhibitor, mavacamten, has recently been approved as a first-in-class...

Comparative Influences Of Betablockers And Verapamil On Cardiac Outcomes In Hypertrophic Cardiomyopathy

Archive ouverte | Pinto, Giuseppe | CCSD

International audience. Guidelines recommend betablockers as first line therapy in symptomatic patients with hypertrophic cardiomyopathy and non-dihydropyridine calcium channel blockers, particularly verapamil, as t...

First-in-man use of a cardiovascular cell-derived secretome in heart failure. Case report

Archive ouverte | Menasché, Philippe | CCSD

International audience. Background There is increased evidence that the effects of stem cells can mostly be duplicated by administration of their secretome which might streamline the translation towards the clinics....

Chargement des enrichissements...